| |
| |
|
| Insider
Information: |
Sachdev Amit |
| Relationship: |
|
| City: |
Cambridge |
| State: |
MA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
2 |
|
| Direct
Shares |
71,325 |
|
|
Indirect Shares
|
7,447 |
|
|
| Direct
Value |
$24,511,741 |
|
|
|
Indirect Value
|
$3,299,393 |
|
|
| Total
Shares |
78,772 |
|
|
| Total
Value |
$27,811,135 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Vertex Pharmaceuticals Inc |
VRTX |
EVP Chief Patient & Ex... |
2024-05-15 |
55,325 |
2024-05-15 |
7,447 |
Premium* |
|
|
Celladon Corp |
CLDN |
|
2022-03-11 |
16,000 |
2020-03-12 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
193 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 5 of 8
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Chief Patient Officer |
• – – |
2022-02-24 |
4 |
D |
$227.86 |
$1,678,872 |
D/D |
(7,368) |
48,210 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, CRO |
• – – |
2018-07-16 |
4 |
OE |
$96.87 |
$166,520 |
D/D |
1,719 |
48,381 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Chief Patient Officer |
• – – |
2020-05-05 |
4 |
OE |
$131.89 |
$1,761,523 |
D/D |
13,356 |
48,459 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, CRO |
• – – |
2018-11-05 |
4 |
OE |
$86.52 |
$167,935 |
D/D |
1,941 |
48,603 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, CRO |
• – – |
2018-08-03 |
4 |
OE |
$86.52 |
$168,022 |
D/D |
1,942 |
48,604 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, CRO |
• – – |
2018-02-26 |
4 |
OE |
$91.05 |
$196,213 |
D/D |
2,155 |
48,817 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, CRO |
• – – |
2018-08-02 |
4 |
OE |
$91.05 |
$196,213 |
D/D |
2,155 |
48,817 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, CRO |
• – – |
2018-11-02 |
4 |
OE |
$91.05 |
$196,213 |
D/D |
2,155 |
48,817 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, CRO |
• – – |
2019-02-04 |
4 |
OE |
$86.52 |
$364,235 |
D/D |
4,097 |
48,817 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
SVP, Public Policy,Gov Affairs |
• – – |
2010-10-18 |
4 |
AS |
$36.50 |
$36,500 |
D/D |
(1,000) |
49,444 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
SVP, Corp Affairs & Pub Policy |
• – – |
2011-03-03 |
4 |
OE |
$18.93 |
$180,422 |
D/D |
9,531 |
49,685 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
SVP, Public Policy,Gov Affairs |
• – – |
2010-10-15 |
4 |
AS |
$35.00 |
$35,000 |
D/D |
(1,000) |
50,444 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Policy, Access & Value |
• – – |
2014-10-28 |
4 |
OE |
$39.05 |
$468,600 |
D/D |
12,000 |
50,671 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, CRO |
• – – |
2017-10-31 |
4 |
AS |
$142.40 |
$5,802,084 |
D/D |
(40,000) |
50,710 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, CRO |
• – – |
2017-11-15 |
4 |
AS |
$147.29 |
$12,225 |
D/D |
(83) |
50,710 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, CRO |
• – – |
2018-06-29 |
4 |
OE |
$86.52 |
$364,148 |
D/D |
4,096 |
50,758 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
SVP, Corp Affairs & Pub Policy |
• – – |
2010-02-04 |
4 |
A |
$0.01 |
$102 |
D/D |
10,166 |
50,983 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
SVP, Global Gov. Strategy |
• – – |
2013-07-19 |
4 |
OE |
$33.28 |
$744,598 |
D/D |
22,250 |
51,237 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
SVP, Corp Affairs & Pub Policy |
• – – |
2011-01-18 |
4 |
OE |
$18.93 |
$225,532 |
D/D |
11,914 |
51,752 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, CRO |
• – – |
2018-01-22 |
4 |
OE |
$83.36 |
$1,146,200 |
D/D |
13,750 |
52,913 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, CRO |
• – – |
2018-01-29 |
4 |
OE |
$91.05 |
$1,373,489 |
D/D |
15,085 |
54,248 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP Chief Patient & Ext Af Off |
• – – |
2024-02-26 |
4 |
AS |
$425.70 |
$1,278,803 |
D/D |
(3,004) |
55,325 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP Chief Patient & Ext Af Off |
• – – |
2024-05-15 |
4 |
AS |
$430.93 |
$13,790 |
D/D |
(32) |
55,325 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Chief Patient Officer |
• – – |
2022-02-17 |
4 |
D |
$232.51 |
$813,087 |
D/D |
(3,497) |
55,578 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Chief Patient Officer |
• – – |
2021-02-17 |
4 |
D |
$211.75 |
$1,612,053 |
D/D |
(7,613) |
55,929 |
0 |
- |
|
193 Records found
|
|
Page 5 of 8 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
